From bedside to bench--meeting report of the 7th International Conference on cGMP "cGMP: generators, effectors and therapeutic implications" in Trier, Germany, from June 19th to 21st 2015.
During the past decade, our knowledge on the physiology, pathophysiology, basic pharmacology, and clinical pharmacology of the second messenger (cGMP) has increased tremendously. It is now well-established that cGMP, generated by soluble and particulate guanylate cyclases, is highly compartmentalized in cells and regulates numerous body functions. New cGMP-regulated physiological functions include meiosis and temperature perception. cGMP is involved in the genesis of numerous pathologies including cardiovascular, pulmonary, endocrine, metabolic, neuropsychiatric, eye, and tumor diseases. Several new clinical uses of stimulators and activators of soluble guanylate cyclase and of phosphodiesterase inhibitors such as heart failure, kidney failure, cognitive disorders, obesity bronchial asthma, and osteoporosis are emerging. The combination of neprilysin inhibitors-enhancing stimulation of the particulate guanylate cyclase pathway by preventing natriuretic peptide degradation-with angiotensin AT1 receptor antagonists constitutes a novel promising strategy for heart failure treatment. The role of oxidative stress in cGMP signaling, application of cGMP sensors, and gene therapy for degenerative eye diseases are emerging topics. It is anticipated that cGMP research will further prosper over the next years and reach out into more and more basic and clinical disciplines.
Institute of Physiology, University of Würzburg, Röntgenring 9, 97070, Würzburg, Germany. andreas.friebe@uni-wuerzburg.de.
Andreas
A
Friebe
Bayer Pharma AG, Global Drug Discovery, Aprather Weg 18a, 42096, Wuppertal, Germany. peter.sandner@bayer.com.
Peter
P
Sandner
Institute of Pharmacology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany. seifert.roland@mh-hannover.de.
Roland
R
Seifert
D000818:Animals; D002318:Cardiovascular Diseases / Q000188:drug therapy / Q000378:metabolism; D003072:Cognition Disorders / Q000188:drug therapy / Q000378:metabolism; D003226:Congresses as Topic; D006152:Cyclic GMP / Q000037:antagonists & inhibitors / Q000378:metabolism* / Q000627:therapeutic use*; D005858:Germany; D006162:Guanylate Cyclase / Q000378:metabolism; D006801:Humans; D038622:Internationality; D010601:Pharmacology, Clinical / Q000379:methods / Q000639:trends; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D019095:Point-of-Care Systems / Q000639:trends*; D018160:Receptors, Cytoplasmic and Nuclear / Q000378:metabolism; D058028:Research Report; D015290:Second Messenger Systems / Q000187:drug effects / Q000502:physiology; D000071756:Soluble Guanylyl Cyclase; D016896:Treatment Outcome
D010726:Phosphodiesterase Inhibitors; D018160:Receptors, Cytoplasmic and Nuclear; D006162:Guanylate Cyclase; D000071756:Soluble Guanylyl Cyclase; D006152:Cyclic GMP
Guanylyl cyclases; Phosphodiesterases; cGMP